BioLineRx Ltd. (BLRX)

Market Cap	19.08M
Revenue (ttm)	21.99M
Net Income (ttm)	-19.92M
Shares Out	1.20B
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	920,833
Open	0.205
Previous Close	0.202
Day's Range	0.197 - 0.208
52-Week Range	0.190 - 1.680
Beta	0.87
Analysts	Strong Buy
Price Target	5.50 (+2,609.36%)
Earnings Date	Nov 25, 2024

About BLRX

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of ski...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 25, 2011
• Employees: 79
• Stock Exchange: NASDAQ
• Ticker Symbol: BLRX
• Website: https://www.biolinerx.com

Analyst Forecast

According to 2 analysts, the average rating for BLRX stock is "Strong Buy." The 12-month stock price forecast is $5.5, which is an increase of 2,609.36% from the latest price.

Price Target

$5.5

(2,609.36% upside)

Analyst Consensus: Strong Buy